Skip to main content
SpringerLink
Log in

Factors controlling the selectivity and efficiency of tumour damage in photodynamic therapy

  • Published:
Lasers in Medical Science Aims and scope Submit manuscript

Abstract

The scope and potential of the photodynamic therapy of tumors can be enhanced through an adequate control of the factors which improve the selectivity of tumour targeting by the systemically injected photosensitizer and increase the efficiency of photosensitized tumour damage. Promising results are obtained by using hydrophobic photosensitizers which can be specifically transported and released to the tumour by serum lipoproteins, especially low-density lipoproteins. The photosensitizer molecule should possess those structural features which induce a high probability of photoactivation by 700–800 nm light, as well as a high yield of long-lived triplet state. The use of liposome-delivered Zn-phthalocyanine as a second generation phototherapeutic agent for tumours is proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dougherty TJ. Photosensitizers: therapy and detection of malignant tumours.Photochem Photobiol 1987,45:879–90

    Google Scholar 

  2. Zhou C. Mechanisms of tumour necrosis induced by photodynamic therapy.J Photochem Photobiol, B: Biol 1989,3:299–318

    Google Scholar 

  3. Kessel D. Proposed structure of the tumor-localizing fraction of HPD.Photochem Photobiol 1986,44:193–6

    Google Scholar 

  4. Bommer JC, Svejda AJ, Petryka ZJ et al. The relationship between the chemical structure of a tetrapyrrole and the selective fluorescence in tumours. In: Jori G, Perria CA (eds)Photodynamic therapy of tumours and other diseases. Padova: Libreria Progetto 1984:405–18

    Google Scholar 

  5. Brasseur N, Ali H, Langlois R, van Lier JE. Biological activities of phthalocyanines. IX. Photosensitization of V-79 Chinese hamster cells and EMT-6 mouse mammary tumour by selectively sulfonated zinc phthalocyanines.Photochem Photobiol 1988,47:705–11

    Google Scholar 

  6. Jori G. Pharmacokinetic studies with haematoporphyrin in tumour-bearing mice. In: Jori G, Perria CA (eds)Photodynamic therapy of tumours and other diseases. Padova: Libreria Progetto 1984:159–66

    Google Scholar 

  7. Jori G, Beltramini M, Reddi E et al. Evidence for a major role of plasma lipoproteins as haematoporphyrin carriers in vivo.Cancer Lett 1984,24:291–7

    Google Scholar 

  8. Kessel D. Porphyrin-lipoprotein association as a factor in porphyrin localization.Cancer Lett 1986,33:183–8

    Google Scholar 

  9. Brown MS, Kovanen PT, Goldstein JL. Evolution of the LDL receptor concept from cultured animal cells to intact animals.Ann NY Acad Sci 1980,348:48–68

    Google Scholar 

  10. Jori G, Tomio L, Reddi E et al. Preferential delivery of liposome-incorporated porphyrins to neoplasic cells in tumour-bearing rats.Br J Cancer 1983,48:307–9

    Google Scholar 

  11. Garbo GM, Morgan AR. Delivery systems for hydrophobic drugs.J Photochem Photobiol, B:Biol 1988,1:494–5

    Google Scholar 

  12. Candide C, Morlière P, Maziere JC et al. In vitro interaction of the photoactive anticancer porphyrin derivative Photofrin II with low density lipoproteins and its delivery in cultured human fibroblasts.FEBS Lett 1986,207:133–8

    Google Scholar 

  13. Zhou C, Milanesi C, Jori G. An ultrastructural comparative evaluation of tumours photosensitized by porphyrins administered in aqueous solution, bound to liposomes or to lipoproteins.Photochem Photobiol 1988,48:487–92

    Google Scholar 

  14. Jori G, Reddi E. Strategies for tumour targeting by photodynamic sensitizers. In: Kessel D (ed)Photodynamic therapy. Boca Raton: CRC Press, 1989 (in press)

    Google Scholar 

  15. Oseroff AR, Ohuoha D, Hasan T et al. Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cell using monoclonal antibodychlorin e6 conjugates.Proc Natl Acad Sci USA 1986,83:8744–8

    Google Scholar 

  16. Mew D, Wat CK, Towers GHN, Levy JG. Photoimmunotherapy: treatment of animal tumours with monoclonal antibody-hematoporphyrin conjugates.J Immunol 1983,130:1473–7

    Google Scholar 

  17. Henderson BW, Farrell G. Possible implications of vascular damage for tumour cell inactivation in vivo: comparison of different photosensitizers. In: Dougherty TJ (ed)Photodynamic therapy: mechanisms. Washington: Proc SPIE 1065, 1989:2–10

  18. Jori G, Reddi E. Second generation photosensitizers for the photodynamic therapy of tumours. In: Douglas R, Moan J, Ronto G (eds)Light in biology and medicine, Vol. 2. London: Plenum 1990 (in press)

    Google Scholar 

  19. Franck B, Fülling G, Gossmann M et al. Chemical principles in the design of improved porphyrin photosensitizers. In: Hasan T (ed)Advances in photochemotherapy. Washington: Proc SPIE 997, 1988:107–12

  20. Morgan AR, Nonis S, Rampersaud A. New dyes for photodynamic therapy. In: Neckers DC (ed)New directions in photodynamic therapy. Washington: Proc SPIE 847, 1987:106–71

  21. Spikes JD. Phthalocyanines as photosensitizers in biological systems and photodynamic therapy.Photochem Photobiol 1986,43:691–9

    Google Scholar 

  22. Foote CS. Mechanistic characterization of photosensitized reactions. In: Moreno G, Pottier RH, Truscott TG (eds)Photosensitization, NATO ASI Series in Cell Biology, Vol. 15. Berlin: Springer Verlag 1988:125–44

    Google Scholar 

  23. Firey PA, Rodgers MAJ. Photoproperties of silicon naphthalocyanine, a potential photosensitizer for photodynamic therapy.Photochem Photobiol 1987,45:535–8

    Google Scholar 

  24. Ford WE, Richter BD, Kenney ME, Rodgers MAJ. Photoproperties of alkoxy-substituted phthalocyanines with deep-red optical absorbance.Photochem Photobiol 1989 (in press)

  25. Reddi E, Zhou C, Biolo R et al. Liposomeor LDL-administered Zn(II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency.Br J. Cancer 1990 (in press)

  26. Valduga G, Reddi E, Jori G. Spectroscopic studies on Zn(II)-phthalocyanine in homogeneous and microheterogeneous systems.J. Inorg Biochem 1987,29:59–65

    Google Scholar 

  27. Reddi E, Lo Castro G, Biolo R, Jori G. Pharmacokinetic studies with Zn(II)-phthalocyanine in tumour-bearing mice.Br J Cancer 1987,56:597–600

    Google Scholar 

  28. Valduga G, Nonell S, Reddi E, Jori G, Braslavsky SE. The production of singlet molecular oxygen by Zinc(II)phthalocyanine in ethanol and in unilamellar vesicles. Chemical quenching and phosphorescence studies.Photochem Photobiol 1988,48:1–5

    Google Scholar 

  29. Firey PA, Jones TW, Jori G, Rodgers MAJ. Photoexcitation of zinc-phthalocyanine in mouse myeloma cells: the observation of triplet states but not of singlet oxygen.Photochem Photobiol 1988,48:353–60

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology, University of Padova, via Trieste 75, 35121, Padova, Italy

    Giulio Jori

Authors
  1. Giulio Jori
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jori, G. Factors controlling the selectivity and efficiency of tumour damage in photodynamic therapy. Laser Med Sci 5, 115–120 (1990). https://doi.org/10.1007/BF02031372

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02031372

Key words

Search

Navigation